Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Main billing specialty: urology.
Medicare fee-for-service kidney stone management cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 245 | 10,751−1.7%/yr | −1.7%/yr | 4.91.0× | 18% | 11,800 in 2030+1.5%/yr |
| California | 210 | 10,020+0.3%/yr | +0.3%/yr | 3.00.6× | 17% | 11,600 in 2030+2.5%/yr |
| Texas | 182 | 9,000−1.4%/yr | −1.4%/yr | 4.20.9× | 17% | 11,000 in 2030+3.4%/yr |
| New York | 134 | 7,123−2.3%/yr | −2.3%/yr | 4.00.8× | 10% | 7,020 in 2030−0.2%/yr |
| Ohio | 150 | 6,970−0.5%/yr | −0.5%/yr | 6.41.3× | 12% | 7,740 in 2030+1.8%/yr |
| Pennsylvania | 164 | 6,776−2%/yr | −2%/yr | 5.01.0× | 12% | 6,810 in 2030+0.1%/yr |
| Illinois | 148 | 6,158−2.8%/yr | −2.8%/yr | 4.50.9× | 13% | 6,630 in 2030+1.2%/yr |
| New Jersey | 109 | 6,001+1.1%/yr | +1.1%/yr | 5.81.2× | 31% | 7,770 in 2030+4.4%/yr |
| Maine | 11 | 5,521+56%/yr | +56%/yr | 35.47.2× | 0% | 540 in 2030−32%/yr |
| Indiana | 105 | 5,228−0.5%/yr | −0.5%/yr | 7.51.5× | 11% | 6,130 in 2030+2.7%/yr |
| North Carolina | 103 | 4,811−5%/yr | −5%/yr | 4.91.0× | 5% | 5,000 in 2030+0.6%/yr |
| Virginia | 111 | 4,758−1.7%/yr | −1.7%/yr | 4.60.9× | 25% | 4,870 in 2030+0.4%/yr |
| Georgia | 109 | 4,711−1.3%/yr | −1.3%/yr | 5.51.1× | 17% | 5,540 in 2030+2.7%/yr |
| Michigan | 94 | 4,688−5.4%/yr | −5.4%/yr | 5.61.1× | 6% | 4,480 in 2030−0.8%/yr |
| Tennessee | 110 | 4,594−3.3%/yr | −3.3%/yr | 6.61.3× | 25% | 4,840 in 2030+0.9%/yr |
| Massachusetts | 93 | 4,315−1.9%/yr | −1.9%/yr | 4.60.9× | 8% | 4,690 in 2030+1.4%/yr |
| South Carolina | 83 | 4,214−0.8%/yr | −0.8%/yr | 6.21.3× | 7% | 4,820 in 2030+2.3%/yr |
| Arizona | 76 | 3,933−3.7%/yr | −3.7%/yr | 5.41.1× | 10% | 4,060 in 2030+0.5%/yr |
| Maryland | 91 | 3,844−0.6%/yr | −0.6%/yr | 4.40.9× | 68% | 4,210 in 2030+1.5%/yr |
| Missouri | 83 | 3,766−2.6%/yr | −2.6%/yr | 6.11.2× | 19% | 4,330 in 2030+2.4%/yr |
| Washington | 69 | 3,043−3.6%/yr | −3.6%/yr | 4.00.8× | 8% | 3,010 in 2030−0.2%/yr |
| Oklahoma | 58 | 2,956−0.1%/yr | −0.1%/yr | 6.11.2× | 1% | 3,150 in 2030+1.1%/yr |
| Mississippi | 43 | 2,629−1.4%/yr | −1.4%/yr | 7.11.4× | 30% | 2,760 in 2030+0.8%/yr |
| Wisconsin | 63 | 2,490−3.4%/yr | −3.4%/yr | 4.50.9× | 6% | 2,900 in 2030+2.6%/yr |
| Alabama | 53 | 2,415−5.4%/yr | −5.4%/yr | 5.61.1× | 8% | 2,290 in 2030−0.9%/yr |
| Louisiana | 45 | 2,342−1%/yr | −1%/yr | 5.81.2× | 0% | 2,550 in 2030+1.4%/yr |
| Kentucky | 59 | 2,308−6.2%/yr | −6.2%/yr | 5.11.0× | 3% | 2,480 in 2030+1.2%/yr |
| Kansas | 44 | 2,107−0.8%/yr | −0.8%/yr | 5.21.1× | 20% | 2,660 in 2030+4%/yr |
| Colorado | 50 | 2,035+0.6%/yr | +0.6%/yr | 4.20.9× | 23% | 2,670 in 2030+4.6%/yr |
| Minnesota | 47 | 1,837−5.2%/yr | −5.2%/yr | 4.10.8× | 5% | 2,500 in 2030+5.3%/yr |
| Arkansas | 37 | 1,786−2.9%/yr | −2.9%/yr | 4.81.0× | 10% | 1,850 in 2030+0.6%/yr |
| Iowa | 47 | 1,750−0.8%/yr | −0.8%/yr | 4.00.8× | 26% | 1,840 in 2030+0.9%/yr |
| Connecticut | 39 | 1,628−1.4%/yr | −1.4%/yr | 5.01.0× | 4% | 1,890 in 2030+2.5%/yr |
| Oregon | 48 | 1,607−2.1%/yr | −2.1%/yr | 3.90.8× | 18% | 1,870 in 2030+2.6%/yr |
| Nebraska | 35 | 1,512−0.1%/yr | −0.1%/yr | 5.81.2× | 12% | 1,880 in 2030+3.7%/yr |
| Utah | 33 | 1,327−4.4%/yr | −4.4%/yr | 6.11.2× | 22% | 1,410 in 2030+1%/yr |
| Nevada | 26 | 1,008−3.9%/yr | −3.9%/yr | 3.50.7× | 24% | 1,080 in 2030+1.2%/yr |
| New Hampshire | 22 | 921−1.3%/yr | −1.3%/yr | 4.10.8× | 2% | 1,150 in 2030+3.8%/yr |
| West Virginia | 21 | 920−7.2%/yr | −7.2%/yr | 4.50.9× | 0% | 990 in 2030+1.3%/yr |
| Idaho | 20 | 895−1%/yr | −1%/yr | 4.40.9× | 21% | 1,470 in 2030+8.6%/yr |
| Delaware | 19 | 805−2.9%/yr | −2.9%/yr | 4.71.0× | 31% | 860 in 2030+1.1%/yr |
| Montana | 21 | 782−2.2%/yr | −2.2%/yr | 4.10.8× | 2% | 830 in 2030+1%/yr |
| South Dakota | 18 | 618+1.8%/yr | +1.8%/yr | 4.81.0× | 0% | 810 in 2030+4.6%/yr |
| New Mexico | 11 | 549−4.5%/yr | −4.5%/yr | 2.40.5× | 2% | 570 in 2030+0.7%/yr |
| Rhode Island | 9 | 436−3.7%/yr | −3.7%/yr | 4.91.0× | 0% | 440 in 2030+0.3%/yr |
| Vermont | 10 | 397+2.4%/yr | +2.4%/yr | 3.50.7× | 0% | 810 in 2030+13%/yr |
| District of Columbia | 9 | 387+3.4%/yr | +3.4%/yr | 6.21.3× | 32% | 420 in 2030+1.6%/yr |
| Alaska | 10 | 365−1.4%/yr | −1.4%/yr | 3.00.6× | 18% | 400 in 2030+1.5%/yr |
| North Dakota | 10 | 352−6.2%/yr | −6.2%/yr | 3.60.7× | 0% | 360 in 2030+0.5%/yr |
| Hawaii | 7 | 297−1.8%/yr | −1.8%/yr | 2.30.5× | 0% | 290 in 2030−0.2%/yr |
| Wyoming | 7 | 252−3%/yr | −3%/yr | 2.30.5× | 18% | 260 in 2030+0.5%/yr |
Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 76 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 37 companies. The most active:
Product codes: FGB (ureteroscope and accessories, flexible/rigid), LNS (lithotriptor, extracorporeal shock-wave, urological). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 12% of the cases CMS names in Florida; 156 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| BPH procedures | 2,196 | 155,142−6.4%/yr | −6.4%/yr | 148,000 in 2030−0.8%/yr |
| Hysterectomy, hysteroscopy & ablation | 906 | 83,637−1.3%/yr | −1.3%/yr | 95,100 in 2030+2.2%/yr |
| Incontinence, prolapse & sacral neuromodulation | 1,058 | 73,050−1.4%/yr | −1.4%/yr | 83,900 in 2030+2.3%/yr |
| Prostatectomy & nephrectomy | 592 | 37,032−1.1%/yr | −1.1%/yr | 45,600 in 2030+3.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 8 companies reported engagement with surgeons in the covered states worth $1.2M in consulting, speaking, meals and travel tied to these products, about $346 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.